Difference between revisions of "Penpulimab (Anniko)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Hodgkin lymphoma " to "[[Category:Classical Hodgkin lymphoma ") |
|||
| Line 16: | Line 16: | ||
[[Category:Anti-PD-1 antibodies]] | [[Category:Anti-PD-1 antibodies]] | ||
| − | [[Category:Hodgkin lymphoma medications]] | + | [[Category:Classical Hodgkin lymphoma medications]] |
[[Category:NMPA approved drugs]] | [[Category:NMPA approved drugs]] | ||
Revision as of 14:19, 9 June 2023
Note: Penpulimab is approved in China, but does not appear to have a brand name at this time.
Mechanism of action
PD-1 inhibitor
Diseases for which it is used
History of changes in NMPA indication
- 2021-08-05: Approved for treatment of patients with relapsed or refractory ("r/r") classic Hodgkin’s lymphoma ("cHL") after at least second-line systemic chemotherapy treatment.
Also known as
- Code name: AK105